Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.

被引：0
|
作者：
May, Michael S.
Wooster, Margaux
May, Benjamin
Shu, Catherine A.
Henick, Brian S.
Stoopler, Mark
Smith-Marrone, Stephanie
Saqi, Anjali
Mansukhani, Mahesh M.
Riely, Gregory J.
Hershman, Dawn L.
Herzberg, Benjamin
机构：
[1] Columbia Univ Med Ctr, New York, NY USA
[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA
[3] Columbia Univ, Irving Med Ctr, New York, NY USA
[4] NYP Columbia, Bronxville, NY USA
[5] Columbia Univ, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11012
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
    Ganguly, Arghya
    Yoo, Euna
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 536 - 537
  • [2] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Cardona, Andres Felipe
    Recondo, Gonzalo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Advances in the treatment of KRASG12C mutant non-small cell lung cancer
    Shaverdashvili, Khvaramze
    Burns, Timothy F.
    CANCER, 2025, 131
  • [4] An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations
    Strohbehn, Garth W.
    Sankar, Kamya
    Qin, Angel
    Kalemkerian, Gregory P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (14) : 1569 - 1575
  • [5] KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models
    Rosen, Joshua C.
    Nhu-An Pham
    Li, Quan
    Cao, Pinjiang
    Hueniken, Katrina
    Koga, Takamasa
    Radulovich, Nikolina
    Koers, Alex
    Niedbala, Michael
    Ross, Sarah
    Sacher, Adrian
    Tsao, Ming-Sound
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer
    Govindan, R.
    Fakih, M.
    Price, T.
    Falchook, G.
    Desai, J.
    Kuo, J.
    Strickler, J.
    Krauss, J.
    Li, B.
    Denlinger, C.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P. K.
    Hong, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1125 - S1126
  • [7] Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Chour, Ali
    Toffart, Anne-Claire
    Berton, Elodie
    Duruisseaux, Michael
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer
    Sayama, Hiroyuki
    Marcantonio, Diana
    Nagashima, Takeyuki
    Shimazaki, Masashi
    Minematsu, Tsuyoshi
    Apgar, Joshua F.
    Burke, John M.
    Wille, Lucia
    Nagasaka, Yasuhisa
    Kirouac, Daniel C.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 864 - 877
  • [9] KRASG12C G12C Inhibitors in Non-Small Cell Lung Cancer: A Review
    Tang, Min
    Wu, Yijun
    Bai, Xiufeng
    Lu, You
    ONCOTARGETS AND THERAPY, 2024, 17 : 683 - 695
  • [10] KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer
    Suzuki, Shinichiro
    Yonesaka, Kimio
    CANCER SCIENCE, 2022, 113 : 1260 - 1260
12345